This site is intended for healthcare professionals
Cancer-Associated Thrombosis Learning Zone
Declaration of sponsorship Pfizer and Bristol Myers Squibb

eLearning

Declaration of sponsorship Pfizer and Bristol Myers Squibb
Read time: 45 mins
Last updated:25th Nov 2020
Published:25th Nov 2020

Patients with cancer have an increased risk of developing VTE. Find out why this is the case and learn more about the steps that can be taken to prevent this common complication.

The relationship between cancer and venous thromboembolism (VTE) is well-established. Test your knowledge of the clinical risk factors for VTE in cancer and find out what can be done to prevent this common and life-threatening complication. Our eLearning will also give you the opportunity to improve your understanding of the importance of screening for cancer in patients with unprovoked VTE and potentially save lives.

Venous thromboembolism risk in cancer

Venous thromboembolism risk in cancer

Why is VTE so common among patients with cancer and who is most at risk?

Start eLearning

Closing questions Test your knowledge 5 mins
Introduction Introduction to eLearning module 5 mins
Section 1 Pathophysiology 10 mins
Section 2 Prevalence and incidence 5 mins
Section 3 Cancers with higher risk of VTE 8 mins
Section 4 Thrombotic events and occult malignancy 5 mins
Section 5 Summary 2 mins

Course overview

On completion of this module participants should have a good understanding of:

  • why patients with cancer are at higher risk of venous thromboembolism (VTE) compared to the general population
  • which cancer types are associated with the highest risk of VTE and how individual risk can be assessed
  • how the prevalence and incidence of VTE in patients with cancer compares to the general population
  • the importance of cancer screening patients with unprovoked VTE

Evaluation questions will be asked at the end of the module. These are designed to test your knowledge and consolidate your learning.

System Requirements

Welcome: